Clinical trials of the anti-CCR4 antibody Mogamulizumab revealed the depletion of Treg cells in a subset of patients, coupled with extreme infiltration of T cells into the skin, resulting in Steven Johnson Syndrome (OMIM#608579) (86, 87). Here, CCR4 is linked to Stevens-Johnson syndrome.